DRAXIS and University of Toronto Drop Anipryl Lawsuits

Law360, New York (November 19, 2003, 12:00 AM EST) -- DRAXIS Health, the University of Toronto and the University's Innovation Foundation have mutually agreed to settle their lawsuits over canine medicine Anipryl, the organizations said in a statement.

They said the settlement involved no payments. The animal health subsidiary of DRAXIS will continue to license the animal health applications of l-deprenyl technologies owned by UTIF.

On July 28, 2000, the University of Toronto announced that negotiations with drug manufacturer Draxis had ended and that it had filed a $100 million lawsuit claiming that Anipryl belongs the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.